10 powodów, dla których warto wybrać pantoprazol u pacjentów z polipragmazją Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2021
Słowa kluczowe:
inhibitory pompy protonowej, pantoprazol, interakcje leków, gastroprotekcja, eradykacja Helicobacter pylori
##plugins.themes.bootstrap3.article.main##
Abstrakt
Inhibitory pompy protonowej są podstawą farmakoterapii chorób zależnych od kwasu solnego. Pantoprazol, stosowany od roku 1997 r., uznano za lek skuteczny i bezpieczny. Jest on stabilny chemicznie także w wyższym (np. po antiacida) pH żołądkowym, ma wysoką biodostępność i działa długotrwale. Szerokie spektrum wskazań do stosowania pantoprazolu obejmuje leczenie choroby refluksowej przełyku, leczenie choroby wrzodowej żołądka i dwunastnicy, eradykację zakażenia Helicobacter pylori, leczenie dyspepsji czynnościowej, profilaktykę i leczenie gastropatii po niesteroidowych lekach przeciwzapalnych i zespół Zollingera-Ellisona. Zaletą pantoprazolu jest mała liczba interakcji z innymi lekami – szczególnie istotna, jeśli chodzi o leki przeciwpłytkowe (klopidogrel) – ale również z antypiryną, karbamazepiną, cyklosporyną, klarytromycyną, diklofenakiem, naproksenem, nifedypiną, doustnymi lekami antykoncepcyjnymi, takrolimusem, teofiliną, warfaryną, a także etanolem. Pantoprazol to szczególnie korzystny wybór dla pacjentów w starszym wieku, też poddanych leczeniu przewlekłemu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Skrzydło-Radomańska , B. (2021). 10 powodów, dla których warto wybrać pantoprazol u pacjentów z polipragmazją . Medycyna Faktów , 14(2(51), 139-144. https://doi.org/10.24292/01.MF.0221.2
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Robinson M. Clinical Pharmacology of Proton Pump Inhibitors. Drugs. 2003; 63(24): 2739-54.
2. Cheer SM, Prakash A, Faulds D et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management in acid-related disorders. Drugs. 2003; 63: 101-33.
3. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol. 1996; 8(suppl 1): S15-S20.
4. Blume H, Donath F, Warnke A et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Saf. 2006; 29(9): 769-84.
5. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-11.
6. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007; 3(2): 231-43.
7. Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther. 1996; 10: 359-66.
8. Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016; 14(1): 179-209.
9. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16: 800-8; e807.
10. Mathews S, Reid A, Tian Ch et al. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Experiment Gastroenterol. 2010; 3: 11-6.
11. Regula J, Butruk E, Dekkers C et al. Prevention of NSAID-Associated Gastrointestinal Lesions: a Comparison Study Pantoprazole versus Omeprazole. Am J Gastroenterol. 2006; 101: 1747-55.
12. Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Critical Care. 2005; 9: 45-50.
13. Hirota K, Kudo M, Hashimoto H et al. The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy. Anesth Analg. 2005; 101: 1038-41.
14. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today. 2004; 40(suppl A): 9-14.
15. Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1): 85-92.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001; 120: 594-606.
17. Bremer S, Reinhardt L, Sobotta M et al. Pantoprazole does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients. Front Med. 2018; 5: 2-4.
18. Blume H, Donath F, Warnke A et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-84.
19. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized , placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
20. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012; 35(2): 127-39.
21. Li XO, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton-pump inhibiting drugs: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(8): 821-7.
22. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019; 157: 403-12.
23. Bacak BS, Patel M, Tweed E et al. What is the best way to manage GERD symptoms in the elderly? J Fam Pract. 2006; 55: 248-51.
24. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004; 36: 243-7.
25. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013; 347: f4587.
26. Lieber CS. Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Digestion. 1997; 58: 203-10.
27. De Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy and treatment for Helicobacter pylori infection. Lancet. 1995; 345(8953): 806-20.
28. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012; 974594.
29. Zullo A, Ridola L, Francesco VD et al. High-dose esomeprazole and amoxicilline dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Am J Gastroenterol. 2015; 28: 448-51.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28(7): 868-77.
31. Malfertheiner P, Megraud F, O’Morain CA et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
32. Pellicano R, Zagari RM, Zhang S et al. Pharmacological consideration and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018; 64: 310-21.
33. Heinze H, Fischer R, Pfutzer R et al. Lack of interaction between pantoprazole and ethanol. Clin Drug Invest. 2001; 21(5): 345-51.
34. Hartmann M, Zech K, Bliesath H et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999; 37(4): 159-64.
35. Tielemans MM, van Oijen MGH, Mulder CJJ. Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. Eur J Gastroenterol Hepatol. 2012; 24: 201-7.
36. Yeomans N, Lanas A, Labenz J et al. Efficacy of Esomeprazole (20mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. Am J Gastroenterol. 2008; 103: 2465-73.
37. Gąsiorowska A, Janiak M, Waśko-Czopnik D et al. Postępowanie u pacjentów z objawami choroby refluksowej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2019; 3-4: 245-65.
38. Dąbrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Gastroenterology Rev. 2018; 13(1): 6-15.
39. Brenner G, Athman C, Schneider A. Long-term open-label trial: safety and efficacy of continous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012; 36: 37-47.
40. Li YX, Chen FCh, Liu T et al. Pantoprazole (PPZ) inhibits RANKL-Induced osteoclast formation and function in vitro and prevents lipopolysaccharide – (LPS-)induced inflammatory calvarial bone loss in vivo. Stem Cells Int. 2020; 2020: 8829212.
2. Cheer SM, Prakash A, Faulds D et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management in acid-related disorders. Drugs. 2003; 63: 101-33.
3. Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol. 1996; 8(suppl 1): S15-S20.
4. Blume H, Donath F, Warnke A et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Saf. 2006; 29(9): 769-84.
5. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-11.
6. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007; 3(2): 231-43.
7. Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther. 1996; 10: 359-66.
8. Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016; 14(1): 179-209.
9. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16: 800-8; e807.
10. Mathews S, Reid A, Tian Ch et al. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Experiment Gastroenterol. 2010; 3: 11-6.
11. Regula J, Butruk E, Dekkers C et al. Prevention of NSAID-Associated Gastrointestinal Lesions: a Comparison Study Pantoprazole versus Omeprazole. Am J Gastroenterol. 2006; 101: 1747-55.
12. Brett S. Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Critical Care. 2005; 9: 45-50.
13. Hirota K, Kudo M, Hashimoto H et al. The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy. Anesth Analg. 2005; 101: 1038-41.
14. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today. 2004; 40(suppl A): 9-14.
15. Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1): 85-92.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001; 120: 594-606.
17. Bremer S, Reinhardt L, Sobotta M et al. Pantoprazole does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients. Front Med. 2018; 5: 2-4.
18. Blume H, Donath F, Warnke A et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-84.
19. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized , placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89(1): 65-74.
20. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012; 35(2): 127-39.
21. Li XO, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of the proton-pump inhibiting drugs: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(8): 821-7.
22. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019; 157: 403-12.
23. Bacak BS, Patel M, Tweed E et al. What is the best way to manage GERD symptoms in the elderly? J Fam Pract. 2006; 55: 248-51.
24. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004; 36: 243-7.
25. Gatta L, Vakil N, Vaira D et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013; 347: f4587.
26. Lieber CS. Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Digestion. 1997; 58: 203-10.
27. De Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy and treatment for Helicobacter pylori infection. Lancet. 1995; 345(8953): 806-20.
28. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012; 974594.
29. Zullo A, Ridola L, Francesco VD et al. High-dose esomeprazole and amoxicilline dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Am J Gastroenterol. 2015; 28: 448-51.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28(7): 868-77.
31. Malfertheiner P, Megraud F, O’Morain CA et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
32. Pellicano R, Zagari RM, Zhang S et al. Pharmacological consideration and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018; 64: 310-21.
33. Heinze H, Fischer R, Pfutzer R et al. Lack of interaction between pantoprazole and ethanol. Clin Drug Invest. 2001; 21(5): 345-51.
34. Hartmann M, Zech K, Bliesath H et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999; 37(4): 159-64.
35. Tielemans MM, van Oijen MGH, Mulder CJJ. Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. Eur J Gastroenterol Hepatol. 2012; 24: 201-7.
36. Yeomans N, Lanas A, Labenz J et al. Efficacy of Esomeprazole (20mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. Am J Gastroenterol. 2008; 103: 2465-73.
37. Gąsiorowska A, Janiak M, Waśko-Czopnik D et al. Postępowanie u pacjentów z objawami choroby refluksowej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ. 2019; 3-4: 245-65.
38. Dąbrowski A, Stabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Gastroenterology Rev. 2018; 13(1): 6-15.
39. Brenner G, Athman C, Schneider A. Long-term open-label trial: safety and efficacy of continous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012; 36: 37-47.
40. Li YX, Chen FCh, Liu T et al. Pantoprazole (PPZ) inhibits RANKL-Induced osteoclast formation and function in vitro and prevents lipopolysaccharide – (LPS-)induced inflammatory calvarial bone loss in vivo. Stem Cells Int. 2020; 2020: 8829212.